Study of JAK Inhibition in Stem-Like Prostate Cancer (JASPER): A Phase 1b/2a Multicenter Study of Ruxolitinib and Enzalutamide in Castration Resistant Prostate Cancer
Latest Information Update: 21 Oct 2024
At a glance
- Drugs Enzalutamide (Primary) ; Ruxolitinib (Primary)
- Indications Adenocarcinoma; Prostate cancer
- Focus Adverse reactions
- Acronyms JASPER
- 16 Oct 2024 Planned End Date changed from 1 Oct 2028 to 1 Dec 2028.
- 16 Oct 2024 Planned primary completion date changed from 1 Oct 2026 to 1 Dec 2026.
- 16 Oct 2024 Planned initiation date changed from 1 Oct 2024 to 1 Dec 2024.